• Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=11115575; PubMed=22490663).
  
• Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Unspecified (PubMed=11115575; PubMed=22490663).
  

PubMed=3547771; DOI=10.1620/tjem.150.231
Kobari M., Hisano H., Matsuno S., Sato T., Kan M., Tachibana T.
Establishment of six human pancreatic cancer cell lines and their sensitivities to anti-tumor drugs.
Tohoku J. Exp. Med. 150:231-248(1986)

PubMed=7622937; DOI=10.1007/BF02788531
Amikura K., Kobari M., Matsuno S.
The time of occurrence of liver metastasis in carcinoma of the pancreas.
Int. J. Pancreatol. 17:139-146(1995)

PubMed=8872523; DOI=10.1007/BF02787375
Kimura Y., Kobari M., Yusa T., Sunamura M., Kimura M., Shimamura H., Matsuno S.
Establishment of an experimental liver metastasis model by intraportal injection of a newly derived human pancreatic cancer cell line (KLM-1).
Int. J. Pancreatol. 20:43-50(1996)

PubMed=11115575; DOI=10.3892/or.8.1.89
Sun C.-L., Yamato T., Furukawa T., Ohnishi Y., Kijima H., Horii A.
Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines.
Oncol. Rep. 8:89-92(2001)

PubMed=15770730; DOI=10.3748/wjg.v11.i10.1521; PMCID=PMC4305696
Ma J.-H., Patrut E., Schmidt J., Knaebel H.-P., Buchler M.W., Marten A.
Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarcinoma.
World J. Gastroenterol. 11:1521-1528(2005)

PubMed=16912165; DOI=10.1158/0008-5472.CAN-06-0721
Calhoun E.S., Hucl T., Gallmeier E., West K.M., Arking D.E., Maitra A., Iacobuzio-Donahue C.A., Chakravarti A., Hruban R.H., Kern S.E.
Identifying allelic loss and homozygous deletions in pancreatic cancer without matched normals using high-density single-nucleotide polymorphism arrays.
Cancer Res. 66:7920-7928(2006)

CLPUB00416
Oberlin L.
Treatment of pancreatic carcinoma cell lines in vitro and vivo with a monoclonal antibody against the transferrin receptor.
Thesis VMD (2009); Justus-Liebig-Universitat Giessen; Giessen; Germany

PubMed=20037478; DOI=10.4161/cbt.8.21.9685; PMCID=PMC2824894
Kent O.A., Mullendore M.E., Wentzel E.A., Lopez-Romero P., Tan A.-C., Alvarez H., West K.M., Ochs M.F., Hidalgo M., Arking D.E., Maitra A., Mendell J.T.
A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells.
Cancer Biol. Ther. 8:2013-2024(2009)

PubMed=22490663; DOI=10.1016/j.bbrc.2012.03.122
Saiki Y., Yoshino Y., Fujimura H., Manabe T., Kudo Y., Shimada M., Mano N., Nakano T., Lee Y., Shimizu S., Oba S., Fujiwara S., Shimizu H., Chen N., Nezhad Z.K., Jin G., Fukushige S., Sunamura M., Ishida M., Motoi F., Egawa S., Unno M., Horii A.
DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells.
Biochem. Biophys. Res. Commun. 421:98-104(2012)